{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T07:17:22Z","timestamp":1794554242016,"version":"4.9.1"},"reference-count":35,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"unspecified","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,4,3]]},"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Identify the windows of opportunity for the diagnosis of chronic kidney disease (CKD) and the prevention of its adverse outcomes and quantify the potential population gains of such prevention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and setting<\/jats:title>\n                    <jats:p>Observational, population-wide study of residents in the Stockholm and Sk\u00e5ne regions of Sweden between 1 January 2015 and 31 December 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>All patients who did not yet have a diagnosis of CKD in healthcare but had CKD according to laboratory measurements of CKD biomarkers available in electronic health records.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measures<\/jats:title>\n                    <jats:p>We assessed the proportions of the patient population that received a subsequent diagnosis of CKD in healthcare, that used guideline-directed pharmacological therapy (statins, renin-angiotensin aldosterone system inhibitors (RAASi) and\/or sodium-glucose cotransporter-2 inhibitors (SGLT2i)) and that experienced adverse outcomes (all-cause mortality, cardiovascular mortality or major adverse cardiovascular events (MACE)). The potential to prevent adverse outcomes in CKD was assessed using simulations of guideline-directed pharmacological therapy in untreated subsets of the study population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 99 382 patients with undiagnosed CKD during the study period. Only 33% of those received a subsequent diagnosis of CKD in healthcare after 5 years. The proportion that used statins or RAASi was of similar size to the proportion that didn\u2019t, regardless of how advanced their CKD was. The use of SGLT2i was negligible. In simulations of optimal treatment, 22% of the 21 870 deaths, 27% of the 14 310 cardiovascular deaths and 39% of the 22 224 MACE could have been avoided if every patient who did not use an indicated medication for their laboratory-confirmed CKD was treated with guideline-directed pharmacological therapy for CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While we noted underdiagnosis and undertreatment of CKD in this large contemporary population, we also identified a substantial realisable potential to improve CKD outcomes and reduce its burden by treating patients early with guideline-directed pharmacological therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-074064","type":"journal-article","created":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T03:55:21Z","timestamp":1713585321000},"page":"e074064","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Are there lost opportunities in chronic kidney disease? A region-wide cohort study"],"prefix":"10.1136","volume":"14","author":[{"given":"Johan","family":"Sundstr\u00f6m","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, Clinical Epidemiology, Uppsala University, Uppsala, Sweden"},{"name":"The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Norhammar","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Department of Medicine, Karolinska Institutet, Solna, Stockholm, Sweden"},{"name":"Capio S:t G\u00f6rans Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stelios","family":"Karayiannides","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden"},{"name":"Center for Diabetes, Academic Specialist Center, Region Stockholm, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Bodeg\u00e5rd","sequence":"additional","affiliation":[{"name":"Cardiovascular, Renal and Metabolism, Medical Department, BioPharmaceuticals, AstraZeneca PLC, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Gustafsson","sequence":"additional","affiliation":[{"name":"Sence Research AB, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Cars","sequence":"additional","affiliation":[{"name":"Sence Research AB, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Eriksson Svensson","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Renal Medicine, Uppsala University, Uppsala, Sweden"},{"name":"Uppsala Clinical Research Center, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"\u00c4rnl\u00f6v","sequence":"additional","affiliation":[{"name":"Division of Family Medicine, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden"},{"name":"School of Health and Social Studies, Dalarna University, Falun, Dalarna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,4,19]]},"reference":[{"key":"2025121403552807000_14.4.e074064.1","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2022.100438","article-title":"Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2\u00b74 million patients from 11 countries: the Careme CKD study","volume":"20","author":"Sundstr\u00f6m","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"2025121403552807000_14.4.e074064.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30045-3"},{"key":"2025121403552807000_14.4.e074064.3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158765","article-title":"Global prevalence of chronic kidney disease - A systematic review and meta-analysis","volume":"11","author":"Hill","year":"2016","journal-title":"PLoS One"},{"key":"2025121403552807000_14.4.e074064.4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.14745"},{"key":"2025121403552807000_14.4.e074064.5","doi-asserted-by":"crossref","DOI":"10.1053\/j.ajkd.2018.01.002","article-title":"US renal data system 2017 annual data report: epidemiology of kidney disease in the United States","volume":"71","author":"Saran","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"2025121403552807000_14.4.e074064.6","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.09.003"},{"key":"2025121403552807000_14.4.e074064.7","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0027"},{"key":"2025121403552807000_14.4.e074064.8","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.444"},{"key":"2025121403552807000_14.4.e074064.9","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.31"},{"key":"2025121403552807000_14.4.e074064.10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.18169","article-title":"Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD Registry","volume":"2","author":"Tuttle","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2025121403552807000_14.4.e074064.11","doi-asserted-by":"crossref","first-page":"352","DOI":"10.34067\/KID.0000000000000374","article-title":"Mortality, Healthcare burden, and treatment of chronic kidney disease \u2013 A multinational, observational study (OPTIMISE-CKD)","volume":"5","author":"Tangri","year":"2024","journal-title":"Kidney360"},{"key":"2025121403552807000_14.4.e074064.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"2025121403552807000_14.4.e074064.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233"},{"key":"2025121403552807000_14.4.e074064.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1411430"},{"key":"2025121403552807000_14.4.e074064.15","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-009-9350-y"},{"key":"2025121403552807000_14.4.e074064.16","unstructured":"World Health Organization . WHO collaborating centre for drug Statistics methodology. ATC\/DDD index. 2017. Available: https:\/\/www.whocc.no"},{"key":"2025121403552807000_14.4.e074064.17","unstructured":"World Health Organization . International classification of disease and related health problems, Available: http:\/\/www.who.int\/classifications\/icd\/en"},{"key":"2025121403552807000_14.4.e074064.18","unstructured":"Nordic Medico-Statistical Committee . NOMESCO Classification of Surgical Procedures, 2010. Available: https:\/\/norden.diva-portal.org\/smash\/get\/diva2:970547\/FULLTEXT01.pdf"},{"key":"2025121403552807000_14.4.e074064.19","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1515\/cclm-2013-0741","article-title":"The revised Lund-Malm\u00f6 GFR estimating equation Outperforms MDRD and CKD-EPI across GFR, age and BMI intervals in a large Swedish population","volume":"52","author":"Nyman","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"2025121403552807000_14.4.e074064.20","unstructured":"R Development Core Team Core Team . R: A language and environment for statistical computing. 2011."},{"key":"2025121403552807000_14.4.e074064.21","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v038.i07"},{"key":"2025121403552807000_14.4.e074064.22","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht065"},{"key":"2025121403552807000_14.4.e074064.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2008.01.031"},{"key":"2025121403552807000_14.4.e074064.24","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-42989-z","article-title":"SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis","volume":"13","author":"Mavrakanas","year":"2023","journal-title":"Sci Rep"},{"key":"2025121403552807000_14.4.e074064.25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2017-110888"},{"key":"2025121403552807000_14.4.e074064.26","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/FJC.0000000000000671","article-title":"Does Co-administration of antihypertensive drugs and Statins alter their efficacy and safety? A systematic review and meta-analysis of randomized controlled trials","volume":"73","author":"Kanukula","year":"2019","journal-title":"J Cardiovasc Pharmacol"},{"key":"2025121403552807000_14.4.e074064.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2008.09.038"},{"key":"2025121403552807000_14.4.e074064.28","doi-asserted-by":"crossref","unstructured":"Tangri N , Franz\u00e9n S , Peach EJ , et al . REVEAL CKD: estimated glomerular filtration rate (eGFR) decline before and after a CKD diagnosis among patients with CKD stage 3. presented at the American society of Nephrology kidney week, 2022, Orlando, FL, USA, November 3\u20136. 2022.","DOI":"10.1681\/ASN.20223311S1302b"},{"key":"2025121403552807000_14.4.e074064.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2009.06.004"},{"key":"2025121403552807000_14.4.e074064.30","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/pds.3941","article-title":"The effect of angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker use on mortality in patients with chronic kidney disease: a meta-analysis of observational studies","volume":"25","author":"Qin","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025121403552807000_14.4.e074064.31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of Dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a Prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Wheeler","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025121403552807000_14.4.e074064.32","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.kint.2018.02.014","article-title":"Automated acute kidney injury alerts","volume":"94","author":"Kashani","year":"2018","journal-title":"Kidney Int"},{"key":"2025121403552807000_14.4.e074064.33","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.bpa.2017.08.003","article-title":"Impact of E-alert systems on the care of patients with acute kidney injury","volume":"31","author":"Breighner","year":"2017","journal-title":"Best Pract Res Clin Anaesthesiol"},{"key":"2025121403552807000_14.4.e074064.34","unstructured":"Nationellt programomr\u00e5de . Nationellt v\u00e5rdprogram f\u00f6r kronisk njursjukdom, 2022. Available: https:\/\/d2flujgsl7escs.cloudfront.net\/external\/Nationellt_vardprogram_for_kronisk_njursjukdom.pdf"},{"key":"2025121403552807000_14.4.e074064.35","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019030238"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-074064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T11:55:37Z","timestamp":1765713337000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-074064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,19]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1136\/bmjopen-2023-074064"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-074064","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2023-074064.supp1","asserted-by":"subject"}]},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]}}}